

Application No.: 10/777310

Case No.: 58232US004

REMARKS

Claims 1-29 are pending in the application. Claims 1-20 and 22-29 are canceled herein. Claims 30-44 have been added. Consequently, claims 21 and 30-44 remain under consideration.

Applicants respectfully request reconsideration of the application in view of the amendments and the following remarks.

Amendments to the Claims

Please cancel claims 1-20 and 22-29 without prejudice.

New claims 30-44 recite particular chemical classes of TLR8 agonists. Support for each new claim may be found throughout the application such as, for example, from page 15, line 26 through page 19, line 5. Each of new claims 30-44 depends directly from claim 21, the patentability of which is acknowledged in the Office Action. Consequently, each of the new claims is patentable for at least all of the reasons that claim 21 is patentable.

No new matter is introduced in the new claims.

§ 112 Rejections

Claim 19 stands rejected under 35 USC § 112, first paragraph, as lacking enablement for the entire scope of the claimed method.

Claim 19 has been canceled herein, obviating the rejection.

§ 103 Rejections

Claims 12-18 and 20 stand rejected under 35 USC § 103(a) as being unpatentable over Jurk *et al.*

Claims 12-18 and 20 have been canceled herein, obviating the rejection.

Application No.: 10/777310

Case No.: 58232US004

CONCLUSION

In view of the above, Applicants submit that the application is in condition for allowance. The Examiner is invited to contact Applicants' Representatives, at the below-listed telephone number, if it is believed that doing so may assist prosecution of this application.

In view of the above, it is submitted that the application is in condition for allowance. Reconsideration of the application is requested.

Respectfully submitted,

1/10/2006
Date

By: Christopher D. Gram
Christopher D. Gram, Reg. No.: 43,643
Telephone No.: 651-733-1507

Office of Intellectual Property Counsel
3M Innovative Properties Company
Facsimile No.: 651-736-3833